Nebraska Cancer Specialists
- Research works
- 69 ▲ 11% vs 2013–17
- Citations
- 1.7k 24.4 per fractional work
- Top-10% rate
- 14.1% record average 16.5%
- Open access
- 32% world 28%
Not ranked overall: Nebraska Cancer Specialists is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 5.5×. Every wedge is a field page.
- Veterinary 5.5×
- Medicine 4.0×
- Immunology and Microbiology 3.6×
- Biochemistry, Genetics and Molecular Biology 2.4×
- Health Professions 1.4×
- Pharmacology, Toxicology and Pharmaceutics 1.3×
- Economics, Econometrics and Finance 0.4×
- Psychology 0.1×
- Chemistry 0.1×
- Physics and Astronomy 0.1×
- Agricultural and Biological Sciences 0.0×
- Engineering 0.0×
Who are the top researchers at Nebraska Cancer Specialists?
Ranked on the composite score, Ralph J. Hauke lead among researchers whose main affiliation is Nebraska Cancer Specialists.
- 1 Ralph J. Hauke United States · #587,510 worldwide 125 citations · 21 works
Which keywords describe research at Nebraska Cancer Specialists?
By fractional works in all years, weighted toward what it does more of than the world: Immunotherapy, Chemotherapy, Genetic Mutations, Prognostic Factors, Targeted Therapy, Clinical Trials, Biomarkers and PET Imaging.
- Small-Cell Lung Cancer
- Immune Checkpoint Blockade
- Cancer Risk
- Metastatic Breast Cancer
- Gene Expression Profiling
- Rituximab
- Breast Cancer
- Radioimmunotherapy
- Metastatic Prostate Cancer
- Therapy
- Neoadjuvant Therapy
- Cancer Treatment
- Clinical Guidelines
- Metastasis
- Molecular Characterization
- Tumor Microenvironment
- PET Imaging
- Clinical Trials
- Prognostic Factors
- Chemotherapy
- Immunotherapy
- Genetic Mutations
- Targeted Therapy
- Biomarkers
- Cancer
- Prostate Cancer
- Genomic Profiling
- Cancer Therapy
- Hormone Therapy
- Dosimetry
- Survival Analysis
- Androgen Receptor
- Metastatic
- Radiopharmaceuticals
- Clinical Practice Guidelines
- Cancer Incidence
- Molecular Profiling
- Tumor Markers
- Genomic Profiles
- PD-1 and PD-L1
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunotherapy9▲ 21×14 topics
- Chemotherapy7▲ 14×18 topics
- Genetic Mutations6▲ 17×9 topics
- Prognostic Factors6▲ 19×10 topics
- Targeted Therapy6▲ 38×4 topics
- Clinical Trials5▲ 12×5 topics
- Biomarkers4▲ 10×4 topics
- PET Imaging4▲ 29×4 topics
- Cancer4▲ 3.9×24 topics
- Tumor Microenvironment4▲ 15×7 topics
- Prostate Cancer4▲ 33×4 topics
- Molecular Characterization3▲ 26×4 topics
- Genomic Profiling3▲ 46×2 topics
- Metastasis3▲ 14×8 topics
- Cancer Therapy3▲ 6.4×11 topics
- Clinical Guidelines3▲ 13×5 topics
- Hormone Therapy3▲ 38×2 topics
- Cancer Treatment3▲ 14×6 topics
- Dosimetry2▲ 40×2 topics
- Neoadjuvant Therapy2▲ 16×5 topics
- Survival Analysis2▲ 13×5 topics
- Therapy2▲ 17×5 topics
- Androgen Receptor2▲ 38×1 topic
- Metastatic Prostate Cancer2▲ 78×1 topic
- Metastatic2▲ 50×2 topics
- Radioimmunotherapy2▲ 82×1 topic
- Radiopharmaceuticals2▲ 82×1 topic
- Breast Cancer2▲ 10×6 topics
- Clinical Practice Guidelines2▲ 5.2×9 topics
- Rituximab2▲ 17×2 topics
- Cancer Incidence2▲ 18×3 topics
- Gene Expression Profiling2▲ 27×2 topics
- Molecular Profiling2▲ 22×2 topics
- Metastatic Breast Cancer2▲ 38×2 topics
- Tumor Markers2▲ 35×2 topics
- Cancer Risk2▲ 9.1×4 topics
- Genomic Profiles2▲ 68×1 topic
- Immune Checkpoint Blockade2▲ 42×1 topic
- PD-1 and PD-L12▲ 42×1 topic
- Small-Cell Lung Cancer2▲ 68×1 topic
Which research topics does Nebraska Cancer Specialists publish most on?
By volume in 2022–2025: Radiopharmaceutical Chemistry and Applications, Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers and Palliative Care and End-of-Life Issues.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 1 works
- 2 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 4 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 0 works
- 5 Geriatric Care and Nursing Homes General Health Professions 0 works
- 6 Renal cell carcinoma treatment Pulmonary and Respiratory Medicine 0 works
- 7 Sinusitis and nasal conditions Otorhinolaryngology 0 works
- 8 Lung Cancer Research Studies Oncology 0 works
- 9 Neuroendocrine Tumor Research Advances Epidemiology 0 works
- 10 Prostate Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Nebraska Cancer Specialists's research output changed?
Output in 2018–2022 was 11% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Omaha
- University of Nebraska Medical Center
- Creighton University
- University of Nebraska at Omaha
- Engineering Systems (United States)
- Nebraska Medical Center
- Clarkson College
- CHI Health Creighton University Medical Center - Bergan Mercy
- Children's Hospital & Medical Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.